Vidac Pharma shares encouraging early results from a Phase 2a trial for a rare skin cancer, cutaneous T-cell lymphoma, using its primary drug candidate, VDA-1102.
Asieris Debuts Preliminary Results from Study on APL-1202 Pill Paired with Immune Checkpoint Blocker Tislelizumab for Pre-Surgical Care in Advanced Urinary Bladder Tumors at ASCO-GU 2024 Event.
Nivolumab plus hyaluronidase administered beneath the skin is comparably effective to Opdivo given intravenously for advanced or metastatic clear cell kidney cancer as suggested by study CheckMate -67T.
On Jan 26, Pfizer and Astellas Pharma announced that the European Medicines Agency (EMA) has accepted to review a Type II variation application for the combined use of PADCEV® and KEYTRUDA®.
Dupixent® has been granted FDA approval as the exclusive therapy indicated for pediatric patients over the age of 1 diagnosed with eosinophilic esophagitis (EoE).
CBR-701 (SYS6002), a cutting-edge therapeutic agent aimed at Nectin-4, exhibits promising outcomes in initial human trials with Nectin-4 positive cancer patients.